NASDAQ · Biotechnology

MBRX (MBRX) Stock

$1.16 -14.71% NASDAQ: MBRX Healthcare

Valuation

MetricValue
Price$1.16
Market Cap$6.19M
P/E Ratio-0.08
P/B Ratio0.17
P/S Ratio0.00
EPS (TTM)$-28.42
52-Week High$24.00
52-Week Low$1.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-226.67%
ROA-154.55%
ROCE-166.67%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio1.43

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-31.0M$-30.0M$-27.0M$-25.0M
Net Profit$-16.0M$-29.0M$-30.0M$-22.0M$-34.0M
EPS$-221.75$-380.50$-376.75$-158.00$-28.42
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$84.0M$57.0M$38.0M$17.0M$22.0M
Total Liabilities$5.0M$5.0M$12.0M$11.0M$7.0M
Cash$71.0M$43.0M$24.0M$4.0M$9.0M
Borrowings$0$0$1.0M$0$0

Latest News

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment GlobeNewswire · Jul 6, 2026 MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance Stocktwits · Jun 30, 2026 Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control GlobeNewswire · Jun 30, 2026 Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML GlobeNewswire · Jun 5, 2026 Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-28.0M$-24.0M$-24.0M$-23.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$56.0M$-28.0M$-20.0M$-19.0M$5.0M
Free Cash Flow$-19.0M$-28.0M$-24.0M$-24.0M$-23.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-965.50%
Quick Ratio1.38
Interest Coverage—
Return 1Y-85.31%
Return 3Y-99.02%
Return 5Y-99.81%

Ownership

Insiders Held0.63%
Institutions Held3.33%
Institutions Float Held3.35%
Institutional HolderSharesReport Date
Sabby Management, LLC75,0212026-03-31
Geode Capital Management, LLC32,3292026-03-31
Vanguard Capital Management LLC13,8692026-03-31
HRT Financial LP13,7392026-03-31
Vanguard Fiduciary Trust Co6,0722026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BLRXBioLineRx Ltd. $2.85 -2.45% -1.36 $12.39M 0.00%

About MBRX

MBRX is led by CEO Walter V. Klemp, publicly traded since 2016.

MBRX stock trades at $1.16 with a market capitalization of $6.19M. The stock is valued at a price-to-earnings (P/E) ratio of -0.08, price-to-book of 0.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.16 and $24.00, and currently trades 95.2% below its 52-week high.

On profitability, MBRX generates a return on equity (ROE) of -226.67%, return on capital employed of -166.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides